

Valeria Mariotti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6328819/publications.pdf>

Version: 2024-02-01

16
papers

666
citations

687363

13
h-index

996975

15
g-index

17
all docs

17
docs citations

17
times ranked

1194
citing authors

#	ARTICLE	IF	CITATIONS
1	Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma. <i>Journal of Hepatology</i> , 2019, 70, 700-709.	3.7	112
2	Animal models of biliary injury and altered bile acid metabolism. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1254-1261.	3.8	105
3	Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 497-511.	17.8	73
4	The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1435-1443.	3.8	56
5	Liver diseases in the dish: iPSC and organoids as a new approach to modeling liver diseases. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 920-928.	3.8	53
6	Src kinase inhibition reduces inflammatory and cytoskeletal changes in Î²F508 human cholangiocytes and improves cystic fibrosis transmembrane conductance regulator correctors efficacy. <i>Hepatology</i> , 2018, 67, 972-988.	7.3	42
7	Pathophysiologic implications of innate immunity and autoinflammation in the biliary epithelium. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1374-1379.	3.8	41
8	Animal models of cholestasis: An update on inflammatory cholangiopathies. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 954-964.	3.8	39
9	Î²-catenin and interleukin-1Î²-dependent chemokine (CXCL10) production drives progression of disease in a mouse model of congenital hepatic fibrosis. <i>Hepatology</i> , 2018, 67, 1903-1919.	7.3	38
10	Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease. <i>Journal of Hepatology</i> , 2017, 66, 571-580.	3.7	31
11	New insights on the role of vascular endothelial growth factor in biliary pathophysiology. <i>JHEP Reports</i> , 2021, 3, 100251.	4.9	28
12	Animal models of cholangiocarcinoma: What they teach us about the human disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018, 42, 403-415.	1.5	21
13	Animal models for cystic fibrosis liver disease (CFLD). <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 965-969.	3.8	9
14	Dysregulation of the Scribble/YAP/Î²-catenin axis sustains the fibroinflammatory response in a PKHD1 mouse model of congenital hepatic fibrosis. <i>FASEB Journal</i> , 2022, 36, e22364.	0.5	2
15	749 Inhibition of the CA2+-Inhibited Adenylyl Cyclase 5 Reduces Cyst Growth in Mice With Polycystic Liver Disease (ADPKD) Caused By Defective Polycystin-2. <i>Gastroenterology</i> , 2016, 150, S1046.	1.3	0
16	THU-493-Reciprocal changes in ARID1A and EZH2 are associated with cholangiocarcinoma development in a mouse model of caroli disease with high Yap expression. <i>Journal of Hepatology</i> , 2019, 70, e377-e378.	3.7	0